The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.
作者信息
Godwin Colin D, Bates Olivia M, Garling Eliotte E, Beddoe Mary E, Laszlo George S, Walter Roland B
机构信息
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
出版信息
Br J Haematol. 2020 Apr;189(1):e9-e13. doi: 10.1111/bjh.16406. Epub 2020 Feb 4.
Abstract
摘要
相似文献
1
The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.布鲁顿酪氨酸激酶抑制剂依鲁替尼可消除双特异性抗体介导的T细胞细胞毒性。
Br J Haematol. 2020 Apr;189(1):e9-e13. doi: 10.1111/bjh.16406. Epub 2020 Feb 4.
2
Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma.发现一种高效且选择性的布鲁顿酪氨酸激酶抑制剂，可避免对B细胞非霍奇金淋巴瘤的抗体依赖性细胞介导的细胞毒性效应产生损害。
Signal Transduct Target Ther. 2020 Sep 14;5(1):200. doi: 10.1038/s41392-020-00309-1.
3
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.利用PROTAC介导的降解作用靶向布鲁顿酪氨酸激酶中的C481S依鲁替尼耐药突变
Biochemistry. 2018 Jul 3;57(26):3564-3575. doi: 10.1021/acs.biochem.8b00391. Epub 2018 Jun 14.
4
Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.布鲁顿酪氨酸激酶抑制减轻盲肠结扎穿刺术诱导的小鼠心功能障碍。
Front Immunol. 2019 Sep 6;10:2129. doi: 10.3389/fimmu.2019.02129. eCollection 2019.
5
Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.布鲁顿酪氨酸激酶抑制剂通过调节固有免疫细胞中的 IL-23/IL-17A 抑制咪喹莫特诱导的小鼠银屑病样炎症。
Int Immunopharmacol. 2020 Mar;80:106215. doi: 10.1016/j.intimp.2020.106215. Epub 2020 Jan 24.
6
Novel therapies for relapsed/refractory mantle cell lymphoma.复发/难治性套细胞淋巴瘤的新型疗法。
Best Pract Res Clin Haematol. 2018 Mar;31(1):105-113. doi: 10.1016/j.beha.2017.10.010. Epub 2017 Nov 20.
7
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.泽布替尼对慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者免疫细胞的影响。
Hematol Oncol. 2019 Oct;37(4):392-400. doi: 10.1002/hon.2667. Epub 2019 Sep 13.
8
Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.布鲁顿酪氨酸激酶在原发性恶性人淋巴细胞代谢适应的交汇点。
Sci Rep. 2019 Jul 30;9(1):11069. doi: 10.1038/s41598-019-47305-2.
9
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.克服布鲁顿酪氨酸激酶抑制剂伊布替尼耐药突变的策略。
Future Med Chem. 2018 Feb;10(3):343-356. doi: 10.4155/fmc-2017-0145. Epub 2018 Jan 19.
10
Ibrutinib.伊布替尼
Recent Results Cancer Res. 2018;212:133-168. doi: 10.1007/978-3-319-91439-8_7.
引用本文的文献
1
Protection of CD33-modified hematopoietic stem cell progeny from CD33-directed CAR T cells in rhesus macaques.恒河猴中CD33修饰的造血干细胞后代免受CD33导向的嵌合抗原受体T细胞的攻击。
Blood Adv. 2025 May 27;9(10):2367-2378. doi: 10.1182/bloodadvances.2024015016.
2
Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders.优化针对嗜酸性粒细胞和肥大细胞疾病的Siglec-8定向免疫疗法。
Cancers (Basel). 2024 Oct 14;16(20):3476. doi: 10.3390/cancers16203476.
3
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors.新型策略可减轻 T 细胞参与疗法引起的细胞因子释放综合征，重点是使用激酶抑制剂。
Oncoimmunology. 2022 Jun 1;11(1):2083479. doi: 10.1080/2162402X.2022.2083479. eCollection 2022.
本文引用的文献
1
Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia.米哚妥林消除了急性髓细胞白血病中 CD33 导向的 UniCAR 和 CD33-CD3 双特异性抗体疗法。
Br J Haematol. 2019 Sep;186(5):735-740. doi: 10.1111/bjh.15975. Epub 2019 May 23.
2
Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia.依鲁替尼增强了ROR1双特异性T细胞衔接子介导的慢性淋巴细胞白血病细胞毒性作用的疗效。
Br J Haematol. 2019 Jul;186(2):380-382. doi: 10.1111/bjh.15911. Epub 2019 Apr 7.
3
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.在伊布替尼时代，一种用于慢性淋巴细胞白血病有效免疫治疗的 CD19/CD3 双特异性抗体。
Blood. 2018 Aug 2;132(5):521-532. doi: 10.1182/blood-2018-02-830992. Epub 2018 May 9.
4
Bispecific antibodies in haematological malignancies.双特异性抗体在血液恶性肿瘤中的应用。
Cancer Treat Rev. 2018 Apr;65:87-95. doi: 10.1016/j.ctrv.2018.04.002. Epub 2018 Apr 4.
5
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.GDC-0853 的发现：一种在早期临床开发中具有强大、选择性和非共价结合的布鲁顿酪氨酸激酶抑制剂。
J Med Chem. 2018 Mar 22;61(6):2227-2245. doi: 10.1021/acs.jmedchem.7b01712. Epub 2018 Feb 23.
6
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.酪氨酸激酶抑制可增加 FLT3-ITD 的细胞表面定位，并增强急性髓系白血病的 FLT3 导向免疫治疗。
Leukemia. 2018 Feb;32(2):313-322. doi: 10.1038/leu.2017.257. Epub 2017 Aug 14.
7
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.依鲁替尼：用于慢性淋巴细胞白血病的综述。
Drugs. 2017 Feb;77(2):225-236. doi: 10.1007/s40265-017-0695-3.
8
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.激酶抑制剂依鲁替尼用于预防抗CD19嵌合抗原受体T细胞治疗B细胞肿瘤后发生的细胞因子释放综合征。
Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28.
9
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.伊布替尼联合抗 CD19 嵌合抗原受体 T 细胞（CART19）可改善套细胞淋巴瘤的应答。
Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.
10
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.伊布替尼可增强嵌合抗原受体T细胞在白血病中的植入及疗效。
Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26.
Zotero 插件